Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q1 2025 value amounting to $2000.0.

  • Barinthus Biotherapeutics' Cash from Financing Activities fell 9960.24% to $2000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $839000.0, marking a year-over-year decrease of 4153.31%. This contributed to the annual value of $2.2 million for FY2024, which is 1554.49% up from last year.
  • As of Q1 2025, Barinthus Biotherapeutics' Cash from Financing Activities stood at $2000.0, which was down 9960.24% from $837000.0 recorded in Q4 2024.
  • In the past 5 years, Barinthus Biotherapeutics' Cash from Financing Activities registered a high of $121.8 million during Q1 2021, and its lowest value of -$1.4 million during Q3 2021.
  • For the 5-year period, Barinthus Biotherapeutics' Cash from Financing Activities averaged around $15.1 million, with its median value being $358000.0 (2024).
  • The largest annual percentage gain for Barinthus Biotherapeutics' Cash from Financing Activities in the last 5 years was 527777.78% (2022), contrasted with its biggest fall of 10013.05% (2022).
  • Barinthus Biotherapeutics' Cash from Financing Activities (Quarter) stood at $9000.0 in 2021, then skyrocketed by 5277.78% to $484000.0 in 2022, then plummeted by 77.48% to $109000.0 in 2023, then skyrocketed by 667.89% to $837000.0 in 2024, then tumbled by 99.76% to $2000.0 in 2025.
  • Its Cash from Financing Activities stands at $2000.0 for Q1 2025, versus $837000.0 for Q4 2024 and $465000.0 for Q3 2024.